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Abstract 
 
           Effect of Manipulation of Notch Signaling Pathway on Neural Stem Cell Proliferation in 
the Hippocampus Following Traumatic Brain Injury 
 
                                                                                   By 
                                                                          Seung L. Kim 
                     A thesis statement submitted for degree requirement in Mater of Science   
                                                  Virginia Commonwealth University, 2019 
                         Advisor: Dong Sun, MD. PhD. Department of Anatomy & Neurobiology 
The Notch signaling pathway is known as a core signaling system in maintaining neural stem 
cells (NSCs) in embryonic development and adulthood including cell proliferation, maturation, 
and cell fate decision. Proliferation of NSCs persists throughout lifespan in neurogenic niches 
and is often upregulated following neurological insults including traumatic brain injury (TBI). 
Therefore, NSCs are viewed as the brain’s endogenous source for repair and regeneration.   We 
speculate Notch signaling pathway is also involved in injury-induced cell proliferation in the 
neurogenic niche following TBI.  
TBI, which is a leading cause of death and disability, has been a huge burden to our 
society. Many efforts have been made in attempt to treat and manage TBI. In this study, we 
examined the involvement of Notch signaling pathway in injury induced NSC proliferation in the 
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neurogenic niche, by administering exogenous Notch ligands including, Notch agonist or 
antagonist.   
Adult rats were intraventricularly infused with Notch1 receptor agonists (anti-Notch1 
antibody at the dose of 0.5, 2 or 4μg/ml), Notch1 receptor antagonist (recombinant Jagged1 
fusion protein at the dose of 25, 50 or 100μg/ml) or vehicle for 7 days following TBI. 5-bromo-2-
deoxyuridine (BrdU) was administered single daily via intraperitoneal injection to label 
proliferating cells for 7 days post injury.  The animals were sacrificed on the 7th day at 2 hours 
after the last BrdU injection. Sequential vibratome sliced coronal brain sections were processed 
for proliferation marker BrdU, Ki67 or immature neuronal marker DCX staining.  BrdU, Ki67 or 
DCX-labeled cells in the dentate gyrus of the hippocampus were quantified using unbiased 
stereological method.  We found TBI in the form of moderate lateral fluid percussion injury 
(LFPI) induced cell proliferation was further augmented by 7-day infusion of Notch agonist 
(Notch1-2μg/ml) as shown by BrdU and Ki67 labeling. Further, 7-day infusion of Notch 
antagonist (Jagged1-50μg/ml) post-injury greatly reduced the number of BrdU+ cells. However, 
ambiguous dose related responses were also observed where 7-day infusion of higher dose of 
Notch agonist (Notch1-4μg/ml) resulted in reduced cell proliferation. No major changes in the 
numbers of newly generated neurons were observed across the animals, except a slight 
reduction in Notch agonist (Notch1-2μg/ml) and Notch antagonist (Jagged1-50μg/ml) infused 
animals as shown by DCX labeling. 
Infusion of Notch agonist or antagonist affects NSC proliferation following TBI 
suggesting the involvement of Notch signaling pathway in regulating post-TBI NSC proliferation 
in the neurogenic niche. For the unexpected opposite results of higher dosing of Notch 1 
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agonist, the presence of other Notch receptors regulating NSC in the neurogenic niche should 
be considered. Future studies involving selective manipulation of these Notch receptors and 
their downstream effectors would clear some results.   
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                                                 Chapter 1 - Introduction and Background 
Epidemiology 
Traumatic brain injury (TBI) affects millions of people globally each year. According to 
the Centers for Disease Control and Prevention (CDC), in United States alone, 2.8 million TBI 
related deaths, hospitalization, and emergency department visits occurred in 2013. 
Approximately 2.5 million emergency department (ED) visits were TBI-related, approximately 
282,000 TBI-related hospitalizations, and approximately 56,000 resulted in deaths (Taylor et al., 
2017). These deaths do not include number of individuals who did not seek medical care after 
sustaining TBI, which might account for another one fourth of all persons who sustain a TBI 
(Coronado et al., 2011).  
The most common cause of TBI-related to ED visits and hospitalization includes fall, 
being struck by an object, and motor vehicle crashes, the latter being the leading cause of TBI-
related deaths. The highest rate of TBI related ED visits were occurred in young children age of 
0 to 4 and in adult age of 75 or higher primarily caused by fall, accounting for 17.9% increase in 
number of TBI-related ED visits from 2007 to 2013 (Taylor et al., 2017). Although, the rate and 
number of TBI-related ED visits, hospitalization, and deaths involving motor vehicle crashes 
have decreased due to efforts for auto accident prevention and safety regulations (Taylor et al., 
2017). The frequency of brain injury yet remains higher than of any other diseases, such as 
breast cancer, AIDS, Parkinson’s disease and multiple sclerosis (Prins et al., 2013).  
Many TBI survivors develop some form of disability lasting months to life. There are 
currently about 5.3 million people living in United States with TBI related disability (Chauhan, 
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2014), costing approximately $77 billion in average each year (Faul et al.,2010). Currently TBI is 
a best-known epigenetic risk factor for later development of neurodegenerative diseases and 
dementia, people sustaining TBI are approximately 4 times more likely to develop dementia at a 
later stage than people without TBI (Chauhan, 2014). Nevertheless, aftermath of TBI is more of 
a disease process which is associated with immediate and long-term sensorimotor, physical and 
cognitive impairment.  
Annually, much more efforts are provided for therapy and rehabilitation of individuals 
suffering long-term TBI related deficits. However, to this date no effective cure for TBI has been 
found mainly due to the complexity nature of TBI. Recent studies have discovered possibility of 
natural recovery response following TBI (Gao et al., 2009), suggesting occurrence of innate 
response mechanism for repair and regeneration within the brain (Sun, 2014).  
Mechanism and Biomechanics of TBI 
TBI is caused by a physical force applied on the head that leaves an impact, penetration, 
or rapid movement of the brain within the skull which results in altered mental state (Prins et 
al., 2013). The damage to the brain can vary from structural to biochemical levels potentially 
leading to cognitive and behavioral dysfunction depending on how the injury was induced. 
Most traumatic events that cause mechanical insults to the brain can be classified as an impact 
and non-impact injury. Impact injury occurs when immediate force contacts the skull causing 
deformation and brain tissue damage (Bauer et al., 2015). Impulse (non-impact) injury occurs 
when a force such as blast waves or rapid acceleration causes sudden and rapid head 
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movements causing brain tissue damage without causing deformation to skull (Bauer et al., 
2015, Prins et., al 2013).  
TBI can be classified into primary event and secondary event. Primary event is due to 
mechanical tissue damage involving immediate neuronal damage from axonal shearing, often 
completed within seconds of impact (Sun, 2014, Yarham and Absalom, 2008). TBI can be further 
broken down into focal and diffuse injury depending on the location of the tissue damage. Focal 
injury occurs in specific area of the brain with a mechanical force vector delivered to a reduced 
intracranial region, often results in contusion, subdural, and epidural hematoma. Diffuse injury 
is more scattered and is not linked to specific focus of destructive tissue damage. Rather it 
shows widely distributed structural damages scattered along neuronal or vascular components, 
involving diffuse neuronal damage, neuronal perturbation or disconnection (McGinn et al., 
2016).      
However, the secondary event can happen from minutes to days from primary impact 
and consists of a complex cascade of ischemia, excitotoxicity, and metabolic failure which 
results in further cell death and dysfunction (Galgano et al., 2017, McIntoshi 1996). Because of 
the complexity of effect, secondary injury is often considered more devastating (Reilly, 1997). 
Pathology of TBI 
TBI of varying levels of severity has been associated with neural and cognitive changes 
that usually persist chronically years after the initial injury, which are often associated with 
damage to white matter integrity (Kraus et al., 2007, Hayes et al., 2015, Miller et al., 2016). 
Clinical studies suggest that hippocampus, which plays a key role in memory formation and 
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cognitive function, is particularly vulnerable to secondary insults (Sun, 2014). Electrophysiologic 
studies show TBI can result in changes in hippocampal circuitry which affect excitatory and 
inhibitory synaptic transmission, causing hippocampal dysfunction (Reeves et al., 1997). These 
excitatory and inhibitory changes in the brain is believed to be associated with altered 
glutamatergic and GABAergic function following posttraumatic episode (Cohen et al., 2007). 
Hippocampal injury is often associated with cognitive impairments such as memory loss, 
decreased rate of information processing, and cognitive rigidity, and often manifested into 
behavioral deficits such as lack of impulse control, increased agitation, and mood lability 
(Hilton, 1994). These deficits are the hallmark of brain trauma, which is commonly observed 
among TBI patients regardless of their age (Panwar et al., 2018). The cognitive and behavioral 
impairment can have a devastating effect on social behavior and integration into a normal 
lifestyle.  
The behavioral changes can cause development of various psychiatric disorders 
(Castriotta et al., 2007). Studies show that mood disorders are often developed from cognitive 
deficit and impaired emotional processing cause by TBI. Depressive disorders are most common 
mood disorders, including mania, hypomania, and mixed mood states. Mood disorders are 
frequent psychiatric complications of TBI that overlap with prominent anxiety, substance 
misuse, impulsivity and aggression. (Jorge and Arciniegas, 2014). Individuals sustaining TBI are 
susceptible to developing substance use disorder due to the changes in molecular mechanisms 
in mesolimbic system occurred by TBI (Merkel et al., 2017). Also, high prevalence of sleep 
disorders occurs among subjects with TBI, including obstructive sleep apnea, posttraumatic 
hypersomnia, narcolepsy, and periodic limb movements in sleep due to disrupted neurologic 
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signals in the brain (Castriotta, 2007). Other novel psychiatric disorders can trigger onset of TBI, 
such as personality changes, secondary attention-deficit/hyperactivity disorder (SADHD) as well 
as other disruptive disorders, and internalizing disorders that are common to children 
complicating child function and affecting family members post-TBI (Max, 2014) 
Surviving TBI patients are also susceptible to long-term neurological disorders such as 
dementia and Alzheimer’s disease. People sustaining TBI are approximately 4 times more likely 
to develop dementia at a later stage than people without TBI (Chauhan, 2014). A mild TBI can 
put individual with greater risk for Alzheimer’s disease due to a greater neurodegeneration and 
reduced memory performance caused by injury, especially the individuals who are predisposed 
with genetic risk for Alzheimer’s disease (Hayes et al., 2017). Despite the detrimental effects 
that follows TBI including structural deformation, neuronal damage, synaptic disruption, and 
changes in molecular mechanisms, heightened levels of cell proliferation and neurogenesis 
have been observed, this is believed to be in response to brain trauma or insults, which 
suggests that the brain may possess the inherent potential to restore populations of damaged 
or destroyed neurons (Sun, 2014). 
 
Adult Neurogenesis   
Mature mammalian brain has two discrete neurogenic niches for endogenous 
neurogenesis, the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG) and the 
subventricular zone (SVZ) of the lateral ventricle. Neurogenesis in the neurogenic niches are 
believed to persist throughout life (Braun and Jessberger, 2014, Gage, 2002, Lois and Alvarez-
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Buylla A,1993). Adult neurogenesis is known as a sequential process, which require cell 
proliferation and cell fate decision of neural stem cells (NSCs) into transit amplifying cells 
(TACs), surviving cells eventually leading to rise of neuroblasts that could potentially migrate 
and integrate into functional network (Gage, 2000, Kreigstein, and Alvarez-Buylla, 2009).  
During proliferation, NSCs can divide either symmetrically or asymmetrically. Symmetric 
NSC division can be proliferative or differentiative, one NSC can divide into two identical NSCs 
or two neuroprogenitor cells (NPCs) which can differentiate into either glial or neuronal cell 
lineage. Asymmetric division involves one NSC dividing into one NSC and one NPC (Kreigstein, 
and Alvarez-Buylla, 2009). The NPCs that have taken neuronal cell lineage differentiate into new 
neurons. Neuroblasts arise from the ventral SVZ and migrate along the Rostral migratory 
stream (RMS) to the olfactory bulb and differentiate into functional olfactory interneurons 
(Wang et al., 2011, Lim and Alvarez-Buylla, 2016). NPCs from the DG migrate laterally into the 
granule cell layer and exhibit properties of fully integrated mature dentate granule neurons 
(Kempermanm and Gage, 2000). 
In the DG, adult born granule neurons pass through series of developmental stages 
before becoming fully functional neurons. Type 1 cells also known as radial glia-like cells (RGLs), 
can generate proliferating intermediate progenitor cells (IPCs) also known as type 2 cells, these 
type 2 cells can give rise to neuroblasts which subsequently differentiate into immature 
neurons, then mature granule neurons (Figure 1.1. a. Aimone et al., 2014). During the 
maturation process, dendrites of the new neurons extend into molecular zone while the axon 
extends into CA3 region led by both intrinsic and extrinsic factors (Aimone et al., 2014), at 
approximately 10-11 days following generation (Zhao et al., 2006). Dendritic arborization and 
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axonal projections take place between 2-3 weeks after birth and begin to approach 
physiologically and anatomically mature neuron by 4-8 weeks after birth (Aimone et al., 2014). 
About 10 weeks post proliferation, the surviving new cells become dentate granule 
neurons (Sun et al., 2007). Mature adult born granule neurons become functionally 
incorporated into circuitry of the hippocampus, receiving synaptic inputs, fire action potentials, 
and establish synapses to hilus and CA3 cells. (Gonçalves et al., 2016). Studies show that 
anatomical integration of adult born DG into neuronal circuitry follows a precise sequence of 
connectivity (silent -> slow GABA -> glutamate -> fast GABA) that resembles formation of 
developing hippocampus (Espósito et al., 2005). Which suggests that adult hippocampus 
maintains the same development rule for neuronal integration through adulthood, ensuring the 
functional and structural integrity of the newly formed adult hippocampus circuitry.  
This is consistent with recent findings in adult neurogenesis in DG, which could 
contribute to normal hippocampal functions such as memory formation, pattern integration, 
temporal separation, or encoding familiar environments (Aimone et al., 2014). The same can be 
true for injury-induced neurogenesis in DG of adult hippocampus.  A study in a rat TBI model 
reported the observation that restoration of cognitive recovery of Morris Water Maze (MWM) 
performance was within the similar timeframe (56-60 days post injury) as the anatomical 
integration of newborn DG neurons into hippocampus was observed (Sun et al., 2007). Further 
study found that the inhibition of injury induced cell proliferation in DG of rat hippocampus 
completely abolished the innate cognitive recovery of MWM performance (Sun et al., 2015). 
These observations suggest the involvement of adult born DG granule neurons in both 
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physiological or pathological conditions in brain’s innate response to maintain normal cognitive 
function or promote repair/regeneration.   
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Figure 1.1. Neurogenesis in adult hippocampus. (a) Image extracted from Aimone et al., 2014. 
Developmental stages of adult born granular neuron in DG of hippocampus. Proliferation occurs 
at subgranular zone, differentiation occurs 3 – 7 days, migration and maturation into granule 
cell layer by 2-3 weeks, before functionally integrated into hippocampal circuitry by 4-8 weeks. 
(b) Image of rodent DG displaying cell proliferation (BrdU-positive cells in box) in SGZ of DG. (c) 
Image of rodent DG displaying newly generated adult born DG neurons (DCX-positive neurons 
in box) in the granule cell layer. 
 
a 
b c 
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TBI-induced Neurogenesis in TBI Animal Models  
Over the past three decades various animal models have been developed to replicate 
human TBI with the goal to better understand the underlying pathophysiology and in attempt 
to discover potential treatments for TBI. With studies supporting the similarity of active 
neurogenic regions (SVZ and hippocampus) between human and mammalian brains (Eriksson, 
1998), various animal models have been developed in TBI studies using, dogs, cats, sheep, 
swine, and mouse. Although larger animals are closer in size and physiology to human, rodents 
are often selected for TBI models, mainly due to their modest costs, small size and, 
standardized outcome measurements (Xiong et al., 2013). Among various TBI models, the most 
frequently used are fluid percussion injury (FPI) and controlled cortical impact injury (CCI). 
Other injury models such as weight drop impact acceleration injury (WDIAI) and Blast injury 
model are also used in TBI studies. . FPI uses fluid pressure pulse caused from pendulum impact 
to the intact dura through a craniotomy and produces a focal cortical contusion in brain. The 
percussion produces brief displacement and deformation of brain tissue, replicating clinical 
intracranial hemorrhage, brain swelling, and gray matter damage (Xiong et al., 2013). Lately FPI 
model has been modified to lateral fluid percussion injury model (LFPI), which creates not only 
focal cortical contusion, but it also transmits traumatic injury into subcortical structures 
(Galgano et al., 2017). The injury creates progressive degenerative cascades that persist in 
selectively vulnerable brain regions, including ipsilateral hippocampus, thalamus medial 
septum, striatum and amygdala (Hicks et al., 1996), the results usually associated with 
neurological and cognitive deficits, such as difficulties in memory and movement commonly 
seen in TBI patients (Hamm, 2001). CCI model uses a pneumatic or electromagnetic impact 
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device to drive an impactor onto the exposed intact dura. CCI provides a more controlled injury 
in terms of velocity, force, time and depth of injury as compared to FPI model (Xiong et al., 
2013). CCI is often used to replicate clinical cortical injury, axonal injury, and subcortical injury 
in the thalamus and hippocampus (Galgano et al., 2017). 
 As the result of various TBI models, injury-induced cell proliferation was observed in DG 
and SVZ of animals that received FPI injury (Chirumamilla et al., 2002, Sun et al., 2005, Rice, 
2003), CCI injury (Gao et al., 2009), also WDIAI (Villasana et al., 2014) and blast (acceleration-
impact) injury model (Bye et al., 2011). This cell proliferation response is known to be 
particularly common in TBI-stimulated endogenous response in both DG and SVZ, and the cell 
increases is rather transient (Sun, 2016). The injury induced (FPI) proliferated cells peak at 2nd 
day post injury and were only observable during the first week in SGZ of DG (Figure 1.2. a Sun et 
al., 2005). Unlike proliferation, different injury models reported varying results of neuronal 
generation post-TBI. It is known to arise from variation of injury models such as intensity of the 
injury, tissue harvest time and processing method, markers used for quantification (Sun, 2016), 
even age of the animals used could produce different results due to age related neuronal/glial 
cell fate decision in neuronal maturation process (Figure 1.2. b Sun et al., 2005). 
Although exact mechanisms for TBI-induced cell proliferation and neurogenesis is 
unclear, many studies have reported possible involvement of growth factors in neuro-
regenerative process, such as basic fibroblast growth factor (bFGF), Insulin-like growth factor 
(IGF), epidermal growth factor (EGF), or vascular endothelial growth factor (VEGF) (Lee and 
Agoston, 2010, O’Kusky, 2012, Sun et al., 2009,2010, Thau-Zuchman et al., 2010). Similarly, 
modulatory attempts have been made to unveil underlying mechanisms for cell proliferation 
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and neurogenesis via exogenous administration of growth factors for means to enhance natural 
neurogenerative processes. Studies reported post-TBI animals infused with recombinant VEGF 
increased cell proliferation in SVG along with enhanced neuroprotective effects such as 
neurogenesis and angiogenesis (Thau-Zuchman et al., 2010) and survivability of newly 
generated neurons (Lee and Agoston, 2010). Other pharmacological treatment such as Statin 
has been found effective in promoting neurogenesis and cognitive function in TBI animals (Lu et 
al., 2007). Intraventricular infusion of growth factors such as bFGF (Sun et al., 2010) and EGF in 
TBI induced animals had a significant enhancement in cell proliferation in the hippocampus and 
SVZ, while showing a drastic improvement in cognitive functional recovery of the injured adult 
animals (Figure. 1.3. Sun et al., 2009). 
While the enhancement of cell proliferation and neurogenesis involving cognitive 
functional recovery has been observed in many adult TBI-animal models (Sun et al., 2009, Sun 
et al.,2010, Sun et al., 2016), the molecular mechanism responsible for maintaining cell 
proliferation, differentiation, and restoration of neuronal function remains unknown. However, 
emerging evidences suggest the possible involvement of Notch signaling pathway as a key 
mechanism in regulating adult NSC proliferation and neurogenesis in neurogenic niches such as 
SVZ and DG of hippocampus. Notch signaling pathway functions as regulatory signaling system 
during embryonic development in maintenance of NSC proliferation and cell fate decision in 
neurogenic regions (Artavanis-Tsakonas et al., 1999). Studies also confirmed the presence of 
Notch signaling pathway in postnatal and adult brain (Stump, 2002, Traiffort and Ferent, 2015). 
Studies also reported observation of transient increase in Notch signaling activity (Tatsumi, 
2010) along with recovery of cognitive function (Zhang, 2014) in adult brain post-injury, 
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suggesting possible involvement of Notch signaling pathway in brain’s innate response to 
promote repair and regeneration post-TBI. 
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Figure 1.2. Cell proliferation and Neurogenesis in SGZ of DG post-TBI. Image extracted from 
Sun et al., 2005. (A) Number of BrdU-positive cells in SGZ of DG at 2nd, 7th, and 14th day post 
injury. For both Injured juvenile and injured adult rats, Cell proliferation peaks at 2nd day and 
gradually declines by 14th day (**p < 0.01). Significant difference in numbers of BrdU-positive 
cells are still observed by 7th day (*p < 0.05). (B) Percentage of BrdU-positive cells co-localized 
with neuronal (NeuN) and glial (GFAP) marker. Generation of neurons observed in SGZ of DG at 
7th day, 14th day, 28th day of injury. (Animals received 3 doses of BrdU (50 mg/kg body weight) 
I.P injection at 2h intervals on 2nd, 7th or 14th day post FPI injury. Sacrificed 24h after last 
injection)  
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Figure 1.3. Effect of 7-day EGF infusion on cell proliferation in DG, 7 days post injury. Image 
extracted from Sun et al., 2009. Comparison of cell patterns and proliferation between Sham 
animals that received 7-day infusion of vehicle, injured animals that received 7-day infusion of 
vehicle, and injured animals that received 7-day infusion of EGF. (a) Coronal section DG of rat 
Hippocampus, Sham + Vehicle animal displaying lower numbers of BrdU-positive cells along in 
granular cell layer (GSL). (b) TBI + Vehicle animal displaying significantly increased numbers of 
BrdU-positive cells predominately localized in GSL. (c) TBI + EGF animal displaying enhanced 
number of BrdU-positive cells localized in GSL and scattered through hilus. (d) In granular zone 
(GZ), Significant increase in number of BrdU-positive cells in TBI + Vehicle compared to Sham + 
Vehicle (**p < 0.01), further significant increase in number of BrdU-positive cells in TBI + EGF 
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(**p < 0.01) compared to Sham + Vehicle. (e) Similar findings are seen in the hilus. (all animals 
received daily single IP. injections of 5-bromo-2-deoxyuridine (BrdU; 50mg=kg) for 5 
consecutive days.)   
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Notch Signaling Pathway 
Notch gene was first discovered in 1913 by Thomas Hunt Morgan, while studying a 
strain of drosophila melanogaster which were involved in partial loss of function that resulted 
notches in their wing blades (Morgan and Bridges, 1916). However, not much of the gene has 
been known until recently. Studies show that proteins involved in Notch signaling pathway are 
highly conserved and heavily involved with many developmental roles including maintenance, 
proliferation, and differentiation of NSCs (Artavanis-Tsakonas et al., 1999).  Since adult 
neurogenesis occur throughout life, and the Notch pathway proteins are expressed in germinal 
zone of embryonic and adult brain (Stump, 2002), it is highly supportive that Notch signaling 
might be involved in regulating maintenance of postnatal NSCs, which has been confirmed by 
recent transgenic mouse study (Imayoshi et al., 2010).  Moreover, Notch signaling pathway is 
also known to be responsible for regulating neurogenesis in neurogenic niches during 
embryonic development and adulthood (Zhang et al., 2015).  
In mammals, Notch gene transcribes a highly evolutionary conserved large 
transmembrane protein that acts as receptor for DSL (Delta, Serrate, Lag-2) family of ligands 
(Xiao et al, 2009). There are 4 known heterodimeric receptors resulting from proteolytic 
cleavage (S1) form Golgi-network (Logeat et al., 1998), referred to as Notch1, Notch2, Notch3, 
and Notch4. The proteolytic cleavages by furin-like protease are thought to contribute to net 
signal activity by facilitating exocytosis of Notch (Lake et al., 2009), which are expressed on cell 
surface with one extracellular region, a single-pass transmembrane, and a small intracellular 
region (Artavanis-Tsakonas et al., 1999). The extracellular domain of Notch receptor contains 
various number of EGF like repeats and this is where ligands are known to interact with the 
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receptor (Xiao et al, 2009). In postnatal brain, Notch1 is localized in subventricular and 
ventricular germinal zones, whereas Notch2 and Notch3 are more highly localized in Ventricular 
zones. Notch1 and Notch3 are expressed along the inner aspect of the dentate gyrus, and 
Notch2 is expressed in the external granular cell layer (Irvin et al., 2001). All Notch receptors 
binds to all DSL ligands at different affinity, and the unbound receptors are constantly 
internalized to be either recycled or broken-down (McGill et al., 2009). Mammals also possess 
highly conserved five Notch ligands, the drosophila Serrate homologs Jagged 1 and Jagged 2, 
and the drosophila Delta homologs Delta-like1, Delta-like3, and Delta-llike4. All Notch ligands 
are single-pass transmembrane polypeptides and includes EGF-like repeats, with a highly 
conserved DSL domain which is known to be necessary for ligand binding onto EGF-like repeats 
expressed on Notch receptor. (Figure 1.4, Chiba, 2006). Because of membrane bound nature of 
both Notch receptors and ligands, Notch signaling is usually involved with direct cell to cell 
interaction known as canonical Notch signaling pathway.  
 The canonical Notch pathway functions as a core signaling system during embryonic 
development, as well as regulation of tissue homeostasis and stem cell maintenance in the 
adult (Artavanis-Tsakonas et al., 1999, D’souza et al., 2010, Gridley, 1997). Defects in the 
expression of Notch pathway proteins or disruption in Notch signaling can result in severe, 
often lethal developmental abnormalities. Mutation in Notch1 is known to be responsible for 
various cancers such as chronic lymphocytic leukemia (Vavrova E et al., 2017), and T-cell acute 
lymphoblastic leukaemia (Sanchez-Martin and Ferrando, 2017) also haploinsufficiency of Notch 
is associated with aortic disease (Garg et al., 2005). Mutation in Notch2 causes severe 
progressive bone loss such as Hajdu-Cheney syndrome which can lead to facial anomalies and 
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development of osteoporosis (Isidor et al., 2011, Simpson et al., 2011), and haploinsufficiency 
of either Jagged 1 or Notch2 is associated with Alagille syndrome (McDaniell et al., 2006). 
Defects in Notch3 is thought to be responsible for intractable chronic pain such as fibromyalgia 
and neuropathic pain (Rusanescu and Mao, 2014), and is also related to development of facial 
anomalies and meningocele related neurologic dysfunction in human (Gripp et al., 2015). 
Notch4 has been identified as a candidate susceptibility receptor for schizophrenia, however 
the studies have been inconclusive. 
In canonical Notch signaling pathway, Notch ligands interacts with Notch receptors in 
two models, cis-inhibition and trans-activation (Figure.1.5. a, D’Souza et al., 2010). Cis-inhibition 
involves, inhibition of binding between the Notch ligand on the signaling cell and the Notch 
receptor on the signal receiving cell which is already bound to Notch ligand on the same cell. 
Cis-inhibition model is a poorly understood and highly controversial. However, a competition 
between trans- and cis- ligand binding to Notch receptor is one of the explanations for the 
ability of Notch ligand to activate or inactivate Notch signaling. Which is consistent with recent 
findings that Notch DSL ligand such as Jagged1 possess binding site for both trans- and cis- 
interactions with Notch receptor (Cordle et al., 2008).  
In trans-activation model, Notch ligand from signaling cell binds onto unoccupied Notch 
receptor expressed on the signal receiving cell (Figure.1.5. b, D’Souza et al., 2010). Upon ligand 
binding, 1) Notch receptor at the cell surface is ubiquitylated by DTX4 (E3 ubiquitin ligase) 
leading to internalization of Notch1 extracellular domain (NECD) by the ligand-expressing cell 
and the 2) internalization of Notch1 intracellular domain (NICD) which consist the membrane 
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anchored fragment of Notch receptor and DTX4 by the Notch receptor-expressing cell in the 
form of bilateral endocytosis (Chastagner et al., 2017).  
Internalized NECD is recycled by the Notch-ligand expressing cell and re-expressed on 
the cell surface, this recycling is required to acquire affinity for receptor in some Notch ligands 
(Heuss et al., 2008). A Disintegrin And Metalloproteinase (ADAM) cleaves (also known as S2 
cleavage) ligand-receptor complex and forms product that is necessary for the formation of 
Notch Intracellular Domain (NICD) (Chastagner et al., 2017). γ-Secretase cleaves (also known as 
S3 cleavage) and releases NICD which translocated into nucleus following cleavage, however 
the process and proteins involved in NICD nuclear translocation is still unclear.  
Upon translocation into the nucleus, NICD binds to a transcription factor, DNA binding 
protein CSL (CBF1 in humans, Suppressor of hairless in drosophilia, LAG in C. elegans). CSL, 
which is encoded by RBP-J gene in mammals, is believed to plays a central role in transducing 
Notch signals into changes in genes expression (Borggrefe and Oswald, 2009). CSL, by a default 
is a repressor protein preventing gene transcription, however NICD binding displaces co-
repressor proteins and histone deacetylase (HDAc) to convert DNA-bound CSL into an activator. 
Meanwhile, NICD with CSL interaction creates an interface that is recognized by co-activator 
MAML (Matermind-like protein 1-3) and gets recruited to form a complex. This tertiary complex 
containing CSL, NICD, MAML is essential for up-regulation of Notch targets (Kovall, 2008). The 
CSL/NICD/MAML co-activator then can recruit histone acetyltransferase p300 (HAc) (Oswald, 
2001) and initiates transcription of Notch target genes such as Hes (hairy enhancer of split 
family members) and Hey (Hes-related with YRPW motif). (Figure. 1.6, Xiao et al., 2009).  
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In Hes family members, Hes1, and Hes5 are known to regulate cell proliferation and 
neuronal differentiation in the nervous system (Kageyama et al., 2007). Hes1 expression is 
known to promote cell proliferation by repressing neuronal transcription factors and inhibiting 
subsequent neurogenesis (Kageyama et al., 2007). Studies have shown Hes1 expression as a 
result of downstream target of Notch signaling, represented as a negative regulator for adult 
hippocampal neurogenesis post-TBI (Zhang et al, 2014), and in the same way Hes1 expression 
improved spatial-learning and memory capacity of adult mice post-TBI (Zhang et al, 2014). Also, 
Hes1 protein works as a transcription repressor for its own expression. Upon induction, Hes1 
protein directly binds to its promotor region of the gene and inhibit its transcription. 
Meanwhile short-lived Hes1 mRNA and Hes1 proteins disappear rapidly (Kageyama et al., 
2007). Thus, Hes1 expression autonomously oscillates (2-3h per period) by a negative feedback, 
this oscillation is very important for cell proliferation and differentiation for neural stem cells, 
because the steady expression inhibits the proliferation and activates neuronal differentiation 
(Baek et al., 2006).  
Numerous studies have been conducted to modulate downstream effects of Notch 
pathway by inhibiting or activating Notch signaling. Notch pathway inhibition by administration 
of γ-gamma secretase inhibitor delayed G1/S-phase transition and committed NSC to 
neurogenesis (Borghese et al., 2010). In contrast, inhibition of γ-gamma secretase facilitated 
the differentiation of human-induced pluripotent stem cells into neural stem cells. (Chen et al., 
2014). Antibody-mediated Notch-ligand receptor binding inhibition downregulated 
transcription factors of the Notch target gene such as HES5 in both mouse and human neural 
stem cells, leading into neuronal cell fate. (Falk et al., 2012). Notch antisense transgenic mice 
 33 
 
with reduced Notch levels exhibited impaired long-term potentiation (LTP) leading to long-term 
depression (LTD), however activation of Notch signal pathway by introducing Notch ligand 
corrected the defect in LTP of Notch antisense transgenic mice (Wang et al., 2004).  
These studies collectively suggest the   cell proliferation and differentiation of NSCs via 
inhibition or activation of either Notch receptor or its downstream effectors. However, there 
are evidences of other signaling activities that intersects with Notch signaling pathway, at the 
level of Notch ligand expression (Hurlbut, 2007). These include VEGF, tumor necrosis factor 
alpha (TNFα), fibroblast Growth Factor (FGF), interlukin-6 (IL6), platelet derived growth factors 
(PDGF) and other factors resulting in upregulation or downregulation of Notch DSL ligands 
(D’Souza et al., Table 1.1). Suggesting manipulation of Notch signaling pathway could be far 
more complicated in vivo. 
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Figure 1.4. Protein structure of Notch receptor and their ligands. Image extracted from Chiba 
et al., 2006. (a) Notch receptors (1-4) expressing highly conserved, various EGF-like repeats. (b) 
Notch ligands, drosophila Serrate homolog Jagged1 and Jagged 2, drosophila Delta homolog 
Delta-like 1 and delta-like 4 (Delta-like 3 is excluded in picture) in mammals, expressing highly 
conserved EGF-like repeats and DSL domain. DSL is a binding site for Notch. LNR includes 
inhibitory function against cleavage. RAM associates with CSL complex. ANK associates with 
proteins to form complex. PEST regulates half-life of Notch proteins.   
(Abbreviations: ANK, ankyrin repeat; CR, cysteine‐rich repeat; DSL, Delta‐Serrate‐Lag2 domain; 
EGF, epidermal growth factor; HD, heterodimerization domain; LNR, Lin‐Notch repeat; NLS, 
nuclear localization signal; PEST, PEST domain; PM, plasma membrane; RAM, ram domain; TAD, 
transactivation domain.)  
a b 
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Figure 1.5. Models for Notch DSL Ligand binding in Notch signaling. Image extracted from 
D’Souza et al., 2010. (a) trans-activation: Notch ligand expressed on signal sending cell binds to 
Notch receptor expressed on the surface of signal receiving cell leading to cleavage 
internalization of NICD, activating Notch. (b) cis-inhibition: Notch ligand binding to Notch 
receptor expressed on the same signal-receiving cell prevents the binding of other Notch 
ligands from signal-sending cell, blocking Notch signaling. (ADAM: A Disintegrin And 
a b 
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Metalloprotease; NICD: Notch Intracellular Domain; CSL: CBF1, Suppressor of Hairless, Lag-1; 
coactivators such as Mastermind-like proteins (MAMLs). 
 
Figure 1.6. Canonical Notch signaling pathway. Image extracted form Xiao et al., 2009. Schematic 
Notch signaling presentation in mammals demonstrating Notch signaling pathway upon ligand (Jagged 
1,2, Delta-like 1,3,4,) binding on Notch receptors (Notch 1-4). Ligand-Notch receptor complex is cleaved 
by enzymes such as ADAM and γ-Secretase. Upon release, NICD translocate into nucleus forming 
transcription complex (NICD-RBPJ-MAMl) which initiates gene transcription of Notch target genes such 
as Hes and Hey, leading cell to proliferative state, preventing neurogenesis. The CSL (RBPJ in human) 
remains inactive, bound to co-repressor in absence of Notch signaling.    
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Table 1.1. Cellular factors that regulate DSL ligand expression. Image extracted from D’Souza et al., 
2010. Various signaling pathways intersecting with Notch pathway via upregulation/downregulation of 
Notch DSL ligands inducing different cell type specific effects.    
a Vascular Endothelial Growth Factor, b Dll: Delta-like, c Tumor Necrosis Factor α, d FGF: Fibroblast 
Growth Factor, e Lipopolysaccharide, f Prostaglandin E2, g Interleukin 6, h Drosophila Epidermal Growth 
Factor Receptor, I Transforming Growth Factor β, j Platelet-derived Growth Factor, k Th: T helper cell 
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Hypothesis 
 TBI is usually associated with upregulated cell proliferation activity in neurogenic niche 
and this endogenous cell response is viewed as brain’s innate ability to promote repair. Since 
Notch signaling pathway is known key regulator in maintenance of NSC proliferation in the 
neurogenic regions, we hypothesize that Notch signaling pathway is responsible for injury-
induced cell proliferation in the neurogenic regions. To test this hypothesis, in this study, we 
examined the involvement of Notch signaling pathway in injury induced neural stem cell 
proliferation in the DG of the hippocampus by administering exogenous Notch agonist or Notch 
antagonist with intraventricular infusion immediately following TBI.  
 
In canonical Notch signaling pathway, Notch ligand-receptor binding interaction 
activates Notch signaling downstream effectors, leading to NSC to maintain proliferative state 
and hinders neuronal differentiation. Therefore, we expect to see enhanced cell proliferation in 
Notch agonists administered animals and reduced cell proliferation in Notch antagonists 
administered animals post TBI. We also expect to see the subsequent hinderance in the 
neurogenesis in Notch agonist administered animals and enhanced neurogenesis in Notch 
antagonist administered animals.     
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Chapter 2- Materials and Methods 
Experimental Animals  
 Sprague-Dawley rats were selected for the study. Three-month-old male rats weighing 
approximately 300g were used for all groups, rats were purchased from Harlan Inc, Indiana. 
Rats were housed at the animal facility in Virginia Commonwealth University and adequate 
food and water were provided as needed, the animals were kept in 12-hour day/night cycles at 
a room temperature. Proper maintenance and care procedures were followed as approved by 
institution of animal care and use committee (IACUC) and in accordance to the guide for care 
and use of laboratory animals provided by Department of health and human services.     
  
Experimental Setup 
 A total of 36 animals were included in the study, all of which received similar care under 
identical conditions. The animals were randomly selected and divided into total of nine groups 
with n=4 for each group: sham, TBI only, TBI-vehicle, TBI - Notch1 agonist-0.5mg/ml, TBI - 
Notch1 agonist-2mg/ml, TBI - Notch1 agonist-4mg/ml, TBI-Notch1 antagonist-25ug/ml, TBI-
Notch1 antagonist-50ug/ml, TBI-Notch1 antagonist-100ug/ml. All animals received seven 
consecutives single daily BrdU I.P. injections at the dose of 50mg/kg, the last injection was given 
at two hours before the animal was sacrificed. All animals were sacrificed at 7 days post injury.   
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Surgical Procedures  
All rats including sham received the same surgical procedures. All instruments which 
contact the surgery area were pre-sterilized following aseptic procedures. The rat was first 
anesthetized in acrylic glass chamber with 5% isoflurane and intubated and ventilated with 2% 
isoflurane gas mixture (30% O2 and 70% N2) and fixed onto a stereotaxic frame with 
continuous anesthesia during the surgery, and a warming pad was inserted underneath the 
animal to maintain body temperature. The respiration and pulse rate, and the temperature 
were constantly monitored during the entire procedure. First, betadine was applied to the 
shaved head to sterilize the surgical site and the animal received midline incision to expose the 
skull, hemostat was used to retract the skin to prepare for craniotomy. All rats received 4.9 mm 
craniotomy on the parietal bone between lambda and bregma sutures over the left hemisphere 
using trephine and dental Dremel tool which had a small dental drill bit attached at the tip. 
Luer-lock syringe hub made from 20-gauge 1½ inch needle was affixed to the craniotomy site 
and was sealed with cyanoacrylate, and dental acrylic was also used to further secure the hub 
to the skull. The rate of anesthesia administration was off at this point, the animal was brought 
back to consciousness by showing paw reflexes before receiving injury. All rats except sham 
received LFPI as described below. After injury, the animal was returned to surgical table, the 
Lure-lock fitting and the acrylic seal was removed. After the righting time was recorded to 
assess injury severity, the animal was then re-anesthetized with 2% isoflurane gas mixture to 
prepare for intraventricular infusion. An Alzet brain infusion cannula (Brain Infusion Kit II; 
DURECT, Cupertino, CA) was implanted into the ipsilateral posterior lateral ventricle 
(coordinates: AP + 0,8mm, lateral 1.4 mm, 3.5 mm under pial surface). The cannula was then 
 41 
 
connected to a mini osmotic pump (Model 1007D) containing vehicle, Notch 1 agonist or 
antagonist at different concentration, which was subcutaneously placed around posterior neck. 
The incision site was sutured using 5.0 polyamide sutures, anesthetic was off, lidocaine 
hydrochloride jelly and antibiotic ointment was applied to keep the animal form infection. 
Intubation tubing was removed, and the animal was left to regain consciousness by showing 
normal breathing patterns. Rats were transferred to a warm cage lined with sterile surgical 
drapes and observed there for three hours before returning to the housing facility.    
 
 
 
 
 
 
 
 
 
 
 
         
 42 
 
Lateral Fluid Percussion Injury 
 A total of 32 rats received LFPI except for sham. After the craniotomy and the Luer-Lock 
hub was sealed and cemented to the skull, a Luer-lock fitting filled with 0.9% saline was 
attached to the hub to test the integrity of the seal. A lateral fluid percussion injury device 
(Figure 2.1) was used for administrating fluid percussion injury (FPI) on all injured animals in the 
study. The fluid pulse is first generated by the impact of the falling pendulum on the stationary 
fluid filled acrylic cylinder, then traveled across the acrylic cylinder onto the target which is the 
animal receiving the injury, the impulse is amplified by a pressure transducer amplifier and 
measured by an oscilloscope (Tektronix). The device was calibrated and prepared by adjusting 
the angle of pendulum to the device and sending and monitoring a few test pulses. The 
adjustment process was repeated until the optimum targeted fluid pulse with moderate 
severity (2.2±0.02 atm) was achieved. Once the device was prepared and the isoflurane was 
turned off, the animal showed paw reflex and then was connected to the device by the Luer-
lock fitting to the hub attachment on the animal and the injury was delivered. Immediately 
after injury, the animal was detached from the device and transferred to the surgical table and 
the righting time was recorded.    
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Figure 2.1. Lateral fluid percussion injury device. Consists of (a) a Luer-lock fitting for animal 
attachment, (b) a fluid filled acrylic cylinder, (c) a pendulum, (d) an oscilloscope, (e) an 
amplifier. The device is custom built for a laboratory use in Virginia Commonwealth University 
by a company currently known as Custom design & Fabrication.      
 
 
 
 
a 
b c 
d 
e 
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Intraventricular Osmotic Mini-pump Infusion 
 A total of 28 injured rats received infusion, 12 rats received Notch1 agonist (Notch1 
activation antibody), 12 rats received Notch1 antagonist (recombinant Jagged 1 fusion protein), 
and the remaining 4 animals received vehicle. Notch1 infusion were prepared by reconstituting 
the drug with the vehicle-a sterile artificial CSF (148mM NaCl, 3mM KCL, 14mM CaCl2, 0.8mM, 
MgCl2, 1.5mM Na2HPO4, and 0.2 mM NaH2PO4 [pH 7.4]). The concentration for Notch1 
activation antibody (Notch extracellular clone 8G10, cat# MAB 5414, Millipore) infusion dose 
was: 0.5μg/ml, 2μg/ml or 4μg/ml. Recombinant human Jagged1/Fc chimera (cat# 1277-JG, R&D 
System) was first incubated with anti-human Fc antibody (cat# I8885, Sigma-Aldrich) for 1hr on 
ice at a ratio of 2:1, and the final desired concentration of Jagged-1 Fc was prepared by 
reconstituting with a sterile artificial CSF. The final concentration for Jagged1 Fc infusion was: 
25μg/ml, 50μg/ml or 100μg/ml. Before infusion, all mini-osmotic pumps used for Notch1, 
Jagged1 or vehicle infusion were first primed in a warm water bath (37°) for 2 hours. The 
infusion was administered for 7 consecutive days at a flow rate of 0.5μL/h.   
 
BrdU Injections 
 BrdU (5-bromo-2-deoxyuridine, Sigma-Aldrich Co.) which incorporates into the DNA of 
mitotically dividing cells and labels them permanently is used as a cell proliferation marker for 
the study. All rats received a single daily intraperitoneal (IP) BrdU injections at the dose of 50 
mg/kg for 7 consecutive days, the last injection was given 2h before the animal was sacrificed.   
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Sacrifice and Tissue Processing 
 Rats were deeply anesthetized in a plexiglass chamber with isoflurane. After reaching 
deep unconsciousness, a surgical gaze soaked in 100% isoflurane was wrapped around the nose 
of the animal to keep from re-gaining consciousness. The animal was first perfused 
transcardially with 400 mL of phosphate-buffered saline (PBS) then with 400mL of 4% 
paraformaldehyde in PBS.  The brain was harvested and transferred into a plastic container pre-
filled with 4% paraformaldehyde in PBS and stored at 4°C for 48 h before sliced. Vibratome 
(Leica) was used for slicing brain into 60μm coronal sections which were collected and placed 
into five 24 well plates pre-filled with 0.01% sodium azide in PBS solution. The sections were 
stored at 4°C and used as needed for immunostaining procedures.   
 
BrdU Immunostaining 
Six sequential sections spaced 480um between containing hippocampi were selected for 
BrdU immunostaining from animals of all groups. A five-day procedure of BrdU immunostaining 
were followed. The brain sections were washed with PBS for 5 min twice, then denatured in 
50% formamide (Sigma) for 1 h at 65°C. They were rinsed with 2X SSC on a shaker for 2 min in 
room temperature twice. The sections were then incubated for further denaturation in 2N HCl 
for 30 min at 37°C. They were rinsed with PBS for 5 min on a shaker at room temperature twice. 
Then the sections were quenched in 3% hydrogen peroxide (Sigma) for 1 h on a shaker at room 
temperature. Finally, they were rinsed with PBS + 0.3% Triton100 solution for 10 min on a 
shaker at room temperature thrice. The sections were then blocked with blocking buffer (PBS + 
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0.3% Triton100, 5% horse serum) over night at 4°C. Following that, the sections were incubated 
with BrdU primary anti-body solution for 48 h on a shaker at 4°C. The primary antibody solution 
is prepared with monoclonal mouse anti-BrdU antibody (Invitrogen) in blocking buffer at 1:2000 
dilution. After that, the sections were first brought back to room temperature, then washed 
with PBS + 0.3% Triton100 on a shaker for 10 min thrice. Sections were blocked with blocking 
buffer for 3 h on a shaker at room temperature. Afterward they were placed in secondary 
antibody solution on a shaker over night at 4°C. The secondary antibody solution is prepared 
with Biotin-conjugated anti-mouse IgG antibody (Vector) in blocking buffer at 1:200 dilution. On 
day five, the section were brought back to room temperature, then washed with PBS for 5 min 
on a shaker thrice. The sections were then incubated with ABC solution for 2 h on a shaker at 
room temperature. ABC solution was prepared with Avidin-biotin complex regent kit (Vector) 
both A and B reagent were mixed in PBS at 1:200 dilution 30 min prior to use. After 2 h of 
incubation in ABC solution, the sections were washed with PBS for 10 min, repeated thrice 
before placed in DAB solution (Sigma). DAB reaction was controlled by simultaneously 
observing color reaction in sections under dissecting microscope.  Upon reaching the adequate 
reaction time, sections were then washed with PBS for 10 min on a shaker at room 
temperature, repeated thrice. Sections were mounted under dissecting microscope using paint 
brushes onto super-frosted microscope slides. Once mounted, they were left out for air dry 
overnight. The mounted slides were counterstained with 0.1% cresyl violet before cover slipped 
using Permount (Fisher).         
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DCX, Ki67 Immunostaining 
Six sequential hippocampal sections 480um in between from animals from all groups 
were selected for immature neuronal marker doublecortin (DCX) or cell prolfeiration marker 
Ki67 immunostaining. Similar five-day procedure was followed as BrdU immunostaining with 
exclusion of formamide and HCl denaturing steps. For DCX, the primary antibody solution is 
prepared with polyclonal goat anti-DCX antibody (Santa Cruz) in blocking buffer at 1:1000 
dilution, the secondary antibody solution is prepared with Biotin-conjugated anti-goat IgG 
antibody (Vector) in blocking buffer at 1:200 dilution. For Ki67, the primary antibody solution is 
prepared with rabbit anti-Ki67 antibody (Abcam) in blocking buffer at 1:500 dilution, the 
secondary antibody solution is prepared with Biotin-conjugated anti-rabbit IgG antibody 
(Vector) in blocking buffer at 1:200 dilution. 
 
Stereological cell quantification 
 All stained sections were observed under an inverted light microscope (1X71, Olympus). 
Visio pharm program (Denmark) stereology software was used for cell quantification for 
counting individual cells in the DG granular zone (GZ) and hilus region in both ipsilateral (injured 
side) and contralateral sides. First, 4x objective was used to identify and locate targeted 
hippocampus, the region of interest was outlined via drawing tool. The GZ which includes both 
SGZ and granular cell layer (GCL) was outlined and counted. For all three markers, the hilus 
region were also outlined and counted. Cell counting was done with 40x objective. Each 
individual BrdU+, Ki67+ or DCX+ cells were counted in the counting frame with the dissector 
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height set at 15 μm and any cells outside of dissector counting frame was omitted in the 
process. The brain section thickness was measured from five random locations of the tissue. 
Each five focal point were measured and averaged for the section thickness. The average 
thickness (t) of the brain was obtained by averaging thickness of all five sections. Estimation of 
total number of cells (n) per brain were obtained by n= ΣQ ¯· (t/h)(1/asf)(1/ssf). ΣQ ¯ represents 
the total number of counted cells. asf represents average sampling fraction, which is set to one 
since the entire region was counted in this study. ssf represents sampling section fraction which 
is also set to 0.125, since only five sections were used per brain each representing 1/8 of total 
hippocampus.         
      
Statistical Analysis 
 The cell proliferation data was analyzed using SPSS software to determine a pairwise 
significances between all nine groups including 3 doses of Notch agonist, 3 doses of Notch 
antagonists, TBI only, TBI+Vehicle, and sham. A one-way analysis of variance (ANOVA) test was 
performed with post-hoc Tukey’s honestly significant difference (HSD) test. A p value less or 
equal to 0.05 was considered statistically significant.     
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Chapter 3 – Results 
 The aim of this study is to determine whether Notch signaling is responsible for injury-
induced neural stem cell proliferation in the neurogenic niche. To test this, Notch1 agonist 
(Notch1 antibody) or antagonist (recombinant Jagged1 fusion protein) at three different doses 
was infused into the lateral ventricle following TBI for 7-days.  To confirm whether similar level 
of injury was received among TBI animals, post-injury righting time was analyzed between the 
drug infusion groups and the vehicle infusion groups. The righting time, which is the time that 
the rat spontaneously turns from a supine position to a natural position, believed to be 
correlated with animal’s neural deficits, is regarded as an indicator for severity of injury (Hamm, 
2001). ANOVA test revealed that right time had no significant differences between groups 
(p=0.125), suggesting that all TBI animals received similar severity of injury.  
To assess the effect of Notch agonist and antagonist infusion on neural stem cell 
proliferation and generation of new neurons in the dentate gyrus (DG) of the hippocampus, 
sections were immunolabeled with three different markers including BrdU, Ki67 and DCX.  
 
Effect of Notch inhibition or activation on cell proliferation at 7-day post-injury –Ki67 study 
To examine the cell proliferation at the time of sacrifice (7 days post-injury), a 
proliferation marker Ki67 was used. Ki67 protein which is strictly associated with cell 
proliferation and exclusively detected within the nucleus during interphase, however most of 
the protein is relocated to the surface of the chromosomes during mitosis (Scholzen, 2000), 
making an ideal marker for examining cell proliferation at the time of sacrifice. Proliferating 
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cells were labeled at the granular zone (including the subgranular zone and the granular cell 
layer) and the hilus region of hippocampal dentate gyrus in both hemispheres. The 
immunostaining patterns demonstrated Ki67-positive cells are predominately localized in 
subgranular zone (SGZ) and some scattered in hilus region (Fig. 3.1). Among all groups (sham, 
TBI-only, TBI-vehicle, TBI-Notch1-0.5μg/ml, TBI-Notch1-2μg/ml, TBI-Notch1-4μg/ml, TBI-
Jagged1-25μg/ml, TBI-Jagged1-50μg/ml, TBI-Jagged1-100μg/ml), more Ki67+ cells were 
observed in injured-only group and in TBI-Notch1-2μg/ml group. (Figure 3.1.a-i).  
Stereological quantitative analysis of Ki67-positive cells in the DG revealed that in the 
ipsilateral granular zone, higher number of Ki67+ cells were only observed in TBI-only animals 
compared to sham and other groups. TBI-vehicle animals had less Ki67+ cells compared to TBI-
only group. Compared to TBI vehicle group, injured animal with Notch1 activator at 3 doses, the 
2μg/ml group had higher number of Ki67+ cells, suggesting Notch1 antibody only at the 2μg/ml 
is sufficient to enhance cell proliferation, lower dose at 0.5μg/ml had no effect whereas a 
higher dose at 4μg/ml had detrimental effect. For Notch1 antagonist Jagged-1 Fc infusion, 
lower dose at 25μg/ml had slightly less Ki67+ cells compared to TBI-vehicle group, whereas 
50μg/ml or 100μg/ml group showed no change. Similar pattern of Ki67+ cell counting was 
found in the contralateral granular zone with higher number of Ki67+ cells in the TBI-only and 
TBI-Notch1-2μg/ml groups compared to all other groups. (Fig. 3-2 a-b) in comparison to both 
sham and injured animal that received 7-day infusion of vehicle, the increased numbers of Ki67-
positive cells in injured only animals weren’t statistically significant, the same was also true for 
increased in numbers of cells observed in injured animals that received 7-day infusion of 
Notch1-2μg/ml. However, a significant decrease in numbers of Ki67-positive cells was observed 
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in injured animals that received 7-day infusion of Notch1-4μg/ml (p < 0.01) compared to injured 
only animals (Figure 3.2.a-b). Further comparison revealed a significant decrease in numbers of 
Ki67-positive cells in injured animals infused with Jagged1-25μg/ml (p < 0.01), Jagged1 50 μg/ml 
(p < 0.05) in ipsilateral and Jagged1-25μg/ml (p < 0.05) in contralateral side to the injured 
hemisphere. Different cell proliferation responses were observed between two Notch agonist 
doses, while injured Notch1-2μg/ml infused animals displayed a significant increase in Ki67-
positive cells compared to injured only animals, injured Notch1-4μg/ml infused animals 
displayed a significant decrease in numbers of cells, the difference between two Notch doses 
were considered significant (p < 0.05). However, no differences were observed between Notch 
antagonist doses. Quantitative analysis of cell proliferation in the hilus region (Figure 3.2c-d) 
revealed no significant differences among groups). 
In the hilus regions, in both ipsi- and contralateral hemisphere, slightly higher number of 
Ki67+ cells were found in the Notch1-2ug/ml group, however, no statistical significance was 
found among all group comparisons (Fig3-2-c&d).  
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Figure 3.1. Cell proliferation at 7th day post-injury. Images of coronal sections of ipsilateral 
dentate gyrus showing Ki67 staining patterns including (a) sham animal, (b) an injured only 
animal, (c) an injured animal who received 7-day vehicle infusion, and injured animals who 
received 7-day infusion of either Notch1 receptor agonists: (d) Notch1-0.5μg/ml, (e) Notch1-
2μg/ml, (f) Notch1-4μg/ml, or Notch1 receptor antagonists: (g) Jagged1-25μg/ml, (h) Jagged1-
50μg/ml, (i) Jagged1-100μg/ml. Immunostaining patterns demonstrate increased numbers of 
Ki67-positive cells, mainly localized in SGZ and some scattered in hilus region, were observed in 
injured only animal compared to sham or other injured animal that received infusion of either 
vehicle or Notch ligands. Increased numbers of Ki67-positive cells were also observed in injured 
Notch1-2μg/ml infused animals, showing more scattered patterns in the hilus region compared 
to injured only animal.  
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Figure 3.2. Quantification of Ki67 positive cells in dentate gyrus at 7th day post-injury.  
Quantitative analysis of cell proliferation in granular zone displayed no significant differences 
between the sham animals and all injured animals, although increase in numbers of Ki67-
positive cells were observed in TBI-only and Notch1-4μg/ml animals compared to sham, no 
significant differences were observed due the variation of the Ki67-positive cells within each 
group. No differences were observed between the injured vehicle infused animals and the 
injured Notch agonist or antagonist infused animals. (a) In the ipsilateral granular zone, the 
injured animals that received 7-day infusion of Notch1 agonist or antagonist displayed a 
significant decrease in numbers of Ki67-positive cells compared to injured only animals: 
Notch1-4μg/ml (p < 0.01), Jagged1-25μg/ml (p < 0.01), Jagged1 50μg/ml (p < 0.05). A significant 
decrease in numbers of Ki67-positive cell is observed between two injured Notch agonists 
infused animals, Notch1-2μg/ml and Notch1-4μg/ml (p < 0.05). (b) In the contralateral granular 
zone, the injured animals who received 7-day infusion of Notch1 agonist or antagonist infusion 
displayed significant decrease in numbers of Ki67-positive cells compared to injured only 
animals: Notch1-4μg/ml (p < 0.05), Jagged1-25μg/ml (p < 0.05). A significant decrease in 
numbers of Ki67-positive cell is observed between two Notch agonists infused animals, Notch1-
2μg/ml and Notch1-4μg/ml (p < 0.05). Quantitative analysis of cell proliferation in (c) ipsilateral 
hilus zone and (d) contralateral hilus zone both reveled no changes in numbers of Ki67 positive 
among the groups. 
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Effect of Notch inhibition or activation on accumulated cell proliferation and survival in the DG   
7 days following -TBI – BrdU study 
To examine the accumulated cell proliferative response following Notch1 manipulation, 
a cell proliferation marker BrdU was given I.P, daily for 7 days during Notch1 agonist or 
antagonist infusion period. When injected, 5-bromo-2-deoxyuridine (BrdU), a thymine analog 
incorporates itself into newly synthesized DNA during S phase substituting for thymine. The 
degree of BrdU incorporation was detected by BrdU antibody staining. Proliferating cells were 
labeled at the granular zone and the hilus region of hippocampal dentate gyrus in both 
hemispheres. The immunostaining patterns demonstrated BrdU-positive cells are mainly 
localized in SGZ and some scattered in hilus region. Compared to sham animal, higher numbers 
of BrdU-positive cells were observed in, injured only, injured animals that received 7-day 
infusion of vehicle, and injured animals that received 7-day infusion of Notch1-2μg/ml (Fig. 3.3, 
a-f). Less BrdU-positive cells were observed in injured animals that received 7-day infusion of 
Jagged1-50μg/ml compared to all other groups (Fig 3.3.a-f).  
From preliminary Ki67+ cell quantification data, Notch1 antibody at 2μg/ml or Jagged-1 Fc at 
50μg/ml were selected as the best dose for Notch1 and Jagged-1, respectively, for further data 
analysis.  Quantification analysis of BrdU-positive cells has shown: 1). In ipsilateral granular 
zone compared to sham group, significantly increased numbers of BrdU+ cells were found in 
injured only (p<0.01), injured vehicle (p<0.05), and injured Notch1-2μg/ml infusion (p<0.05). , 
whereas compared to other injured groups, a significant decrease in numbers of BrdU-positive 
cells were observed in injured animals that received 7-day infusion of Jagged1-50μg/ml (Fig. 
3.4-a). In the contralateral granular zone, similar pattern of BrdU+ cell counting was found. 
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Compared to sham animals, a significant increase in numbers of BrdU-positive cells was 
observed in injured only animals (p < 0.01), injured animals that received 7-day Notch1-2μg/ml 
or vehicle infusion (p < 0.05). In comparison to injured only animals, a significant decrease in 
numbers of BrdU-positive cells were observed in injured animals that received 7-day infusion of 
Jagged1-50μg/ml. No significant differences were observed between injured vehicle infused 
animals and the injured Notch agonist or antagonist infused animals (Figure 3.4.b). 2). In the 
hilus region, quantitative analysis of BrdU-positive cells (Figure 3.4c-d) revealed that compared 
to sham animals, injured only animals, injured-Notch1-2ug/ml group and injured-vehicle group 
had significant increase in the numbers of BrdU-positive cells (p < 0.01). In comparison to 
injured only animals, a significant decrease in numbers of BrdU-positive cells were observed in 
injured animals that received 7-day infusion of Jagged1-50μg/ml (p < 0.01). However, no 
significant differences were observed between injured vehicle infused animals and the injured 
Notch agonist or antagonist infused animals. 
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Figure 3.3. Cell proliferation for 7 days post-injury. Images of coronal sections of ipsilateral 
dentate gyrus showing BrdU staining patterns including (a) sham animal, (b) an injured only 
animal, (c) an injured animal who received 7-day vehicle infusion, (d) an injured animal that 
received 7-day infusion of of Notch agonist, Notch1-2μg/ml, (e) an injured animal that received 
7-day infusion of Notch antagonist, Jagged1-50μg/ml. Immunostaining patterns demonstrated 
BrdU-positive cells are mainly localized in the SGZ and scattered in the hilus regions of injured 
only and injured animal that received 7-day vehicle or Notch1-2ug/ml infusion, compared to 
sham. . Injured Jagged1-50μg/ml infused animals displayed decrease in numbers of BrdU-
positive cells in comparison to sham, injured only, and injured animals that received infusion of 
either vehicle or Notch1-2μg/ml (BrdU-positive cells indicated by arrows). 
 
 
 
   
  
   
 
 
 61 
 
0
10000
20000
30000
40000
Ipsilateral GZ
B
rd
U
+ 
C
el
ls
Cell Proliferation in IP granular zone 7 days post injury 
Sham
FPI only
FPI + Vehicle
FPI+Notch1 2ug/ml
FPI+Jagged1 50ug/ml
a
*
** **
*
0
5000
10000
15000
20000
25000
30000
35000
40000
Contralateral GZ
B
rd
U
+ 
C
el
ls
Cell Proliferation in granular zone 7 days post injury
Sham
FPI only
FPI + Vehicle
FPI+Notch1 2ug/ml
FPI+Jagged1 50ug/ml
b
*
****
 62 
 
 
  
0
5000
10000
15000
20000
25000
30000
Ipsilateral hilus
B
rd
U
+ 
C
el
ls
Cell Proliferation in IP hilus 7days post injury
Sham
FPI only
FPI + Vehicle
FPI+Notch1 2ug/ml
FPI+Jagged1 50ug/ml
c
****
0
5000
10000
15000
20000
25000
30000
Contralateral hilus
B
rd
U
+ 
C
el
ls
Cell Proliferation in CT hilus 7 days post injury
Sham
FPI only
FPI + Vehicle
FPI+Notch1 2ug/ml
FPI+Jagged1 50ug/ml
d
** **
 63 
 
Figure 3.4. Quantification of BrdU positive cells in dentate gyrus for 7 days post-injury. (a) 
Quantitative analysis of cell proliferation in ipsilateral granular zone reveled that compared to 
sham animals, a significant increase in numbers of BrdU-positive cells were observed in injured 
only animals (p < 0.01), and the injured animals who received 7-day infusion of either vehicle (p 
< 0.05), or Notch1-2μg/ml (p < 0.05). In comparison to injured only animals, a significant 
decrease in numbers of BrdU-positive cells was observed in the injured animals with 7-day 
infusion of Jagged1-50μg/ml (p < 0.01). No significant differences were observed among injured 
vehicle infused animals and injured Notch agonist or antagonist infused animals. (b) 
Quantitative analysis of cell proliferation in contralateral granular zone reveled that compared 
to sham animals, a significant increase in numbers of BrdU-positive cells was observed in 
injured only animals (p < 0.01), and the injured animals who received 7-day Notch1-2μg/ml (p < 
0.05). In comparison to injured only animals, a significant decrease in numbers of BrdU-positive 
cells was observed in the injured animals with 7-day infusion of Jagged1-50μg/ml (p < 0.01). No 
significant differences were observed among injured vehicle infused animals and injured Notch 
agonist or antagonist infused animals. (c-d) Quantitative analysis of cell proliferation in the hilus 
region reveled that compared to the sham animals, a significant increase in the numbers of 
BrdU-positive cells was observed in injured only animals (p < 0.01). Increase in the numbers of 
BrdU-positive cells was also observed in injured vehicle infused animals and injury induced 
Notch1-2μg/ml infused animals compared to sham, however, there was no statistical 
significance due to the big standard deviation within group. In comparison to injured only 
animals, a significant decrease in numbers of BrdU-positive cells was observed in the injured 
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Jagged1-50μg/ml infused animals (p < 0.01) in both the ipsilateral and contralateral hilus 
regions. 
 
Effect of Notch inhibition or activation on generation of new neurons-DCX study 
 The proliferated cells in neurogenic regions often differentiate into neuronal cell 
lineage. The neuronal precursor cells and neuroblasts transiently express, a migration 
associated, microtubule binding protein called doublecortin (DCX) in adult mammalian brain 
(Brown et., al 2003). DCX is often used as a marker for neurogenesis for this exclusiveness 
expression of the protein in immature neurons (Tzeng et., al 2016). To examine the effect of 
Notch ligand infusion on hippocampal neurogenesis, DCX antibody was used to label newly 
generated neurons in dentate gyrus of sham, FPI only animals, and FPI animals that received 
either vehicle or Notch ligands infusion. The staining patterns and quantification of DCX-
positive neurons were compared among the groups. Furthermore, DCX-positive neurons with 
each dendritic orientation (horizontal, vertical, and mixed) were also quantified and compared. 
New neurons labeled with DCX were located at the granular zone and the hilus region of 
hippocampal dentate gyrus in both hemispheres. The immunostaining patterns demonstrated 
DCX-positive neurons were predominately localized in granule cell layers displaying dendritic 
extensions of various orientation. Increased numbers of DCX-positive neurons were observed in 
almost all injured animals compared to sham animals, with greater numbers of newly 
generated neurons expressed in injured only, injured vehicle infused, and injured Notch1-
2μg/ml infused and 4μg/ml infused animals. However, decreased numbers of DCX-positive 
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neurons were observed in injured animal that received 7-day infusion of Jagged1-50μg/ml 
compared to sham (Figure.3.5. a-i)    
Quantification analysis of DCX-positive neurons has shown: 1). In ipsilateral granular 
zone, the increase in the numbers of new neurons was significantly higher in injured vehicle 
infused animals (p < 0.01), injured Notch1-4μg/ml (p < 0.01), or Jagged1-25μg/ml (p < 0.05) 
infused animals in comparison to sham animals (Figure 3.6.a). In the contralateral granular zone 
(Figure 3.6.b), compared to sham, a significant increase in numbers of DCX-positive neurons 
were observed in injured animals that received 7-day infusion of either vehicle (p < 0.05) or 
Notch1-4μg/ml (p < 0.05) (Figure 3.7.b). However, no significant difference was observed 
between injured only animals, injured vehicle infused animals, or injured Notch ligand infused 
animals.    
2). In the ipsilateral hilus region (Figure 3.6.c), in comparison to sham, a significant increase in 
the numbers of DCX-positive neurons was observed in injured animals that received 7-day 
infusion of either vehicle (p < 0.01), or Notch1-4μg/ml (p < 0.05). In comparison to injured 
vehicle infusion animals, injured animals that received 7-day infusion of Notch1-2μg/ml 
displayed a significant decrease in numbers of DCX-positive neurons (p < 0.05) (Figure 3.7.c). In 
the contralateral hilus region (Figure 3.6.d), in comparison to sham animals, a significant 
increase in numbers of DCX positive neurons were observed in injured animals that received 7-
day infusion of either vehicle (p < 0.01) or Notch1-4μg/ml (p < 0.01). In comparison to Injured 
only animals, a significant increase was also observed in injured vehicle infused animals (p < 
0.01) and injured Notch1-4μg/ml infused animals (p < 0.01) (Figure 3.7.d). No significant 
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difference was observed between injured vehicle infused animals and injured Notch ligand 
infused animals. 
.  
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Figure 3.5. Generation of new neurons at 7 days post-injury. Images of coronal sections of 
ipsilateral dentate gyrus showing DCX positive neurons (indicated by arrows) including (a) sham 
animal, (b) an injured only animal, (c) an injured animal that received 7-day vehicle infusion, 
injured animals that received 7-day infusion of Notch1 agonist: (d) Notch1-0.5μg/ml, (e) 
Notch1-2μg/ml, (f) Notch1-4μg/ml, or Notch1 antagonist: (g) Jagged1-25μg/ml, (h) Jagged1-
50μg/ml, (i) Jagged1-100μg/ml. Immunostaining patterns demonstrate newly generated 
neurons were predominately localized in granular zone displaying dendric extensions. Increased 
numbers of DCX-positive neurons were observed in the granular zone of almost all injury 
received animals compared to sham, except Jagged1 50 μg/ml infused animals, which displayed 
decrease in numbers of DCX-positive neurons. Greater numbers of DCX-positive neurons were 
observed in injured animals which received infusion of either vehicle or Notch 4 μg/ml (DCX-
positive neurons indicated by arrow). 
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Figure 3.6. Quantification of newly generated neurons in dentate gyrus at 7 days post-injury. 
(a) In the ipsilateral granular zone, compared to sham, a significant increase in the number of 
DCX-positive neurons was observed in injured animals that received 7-day infusion of either 
vehicle (p < 0.01), Notch1-4μg/ml (p < 0.01) or Jagged1-25μg/ml (p < 0.05). No significant 
difference was observed between injured only animals, injured vehicle infused animals, or 
injured Notch ligand infused animals. (b) In the contralateral granular zone, compared to sham, 
a significant increase in the number of DCX-positive neurons was observed in injured animals 
that received 7-day infusion of either vehicle (p < 0.05) or Notch1-4μg/ml (p < 0.05). No 
significant difference was observed between injured only animals, injured vehicle infused 
animals, or injured Notch ligand infused animals.  (c) In the ipsilateral hilus region, in 
comparison to sham, a significant increase in the numbers of DCX-positive neurons was 
observed in injured animals that received 7-day infusion of either vehicle (p < 0.01) or Notch1-
4μg/ml (p < 0.05). In comparison to injured vehicle infusion animals, injured animals that 
received 7-day infusion of Notch1-2μg/ml displayed a significant decrease in numbers of DCX-
positive neurons (p < 0.05). No significant difference was observed between injured only 
animals and injured animals that received infusion of either vehicle or Notch ligands. (d) In the 
contralateral hilus region, in comparison to sham animals, a significant increase in numbers of 
DCX positive neurons was observed in injured animals that received 7-day infusion of either 
vehicle (p < 0.01) or Notch1-4μg/ml (p < 0.01). In comparison to Injured only animals, a 
significant increase was also observed in injured vehicle infused animals (p < 0.01) and injured 
Notch1-4μg/ml infused animals (p < 0.01). No significant difference was observed between 
injured vehicle infused animals and injured Notch ligand infused animals. 
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Chapter 4- Discussion 
 Published studies have found that TBI enhances neural stem cell proliferation in the 
neurogenic regions, and this endogenous neurogenic response contribute to cognitive recovery 
following TBI (Sun et al., 2007).  Unpublished study from our group has further found that TBI 
induces upregulation of Notch signaling pathway protein expression, and this is correspondent 
to neural stem cell proliferation observed following TBI.  As Notch signaling is critical for 
neurogenesis in both developing and adult brain, we speculate that Notch pathway activation 
plays an important role in TBI-induced neurogenic response.  In this study we utilized a Notch 
agonist and an antagonist to assess the role of Notch signaling in post-TBI neurogenesis in the 
hippocampus.  We found that manipulation of Notch pathway activation can affect TBI-induced 
cell proliferation. Specifically, intraventricular infusion of Notch agonist (Notch1 antibody) for 7-
day post-injury did not further augment injury-induced accumulated cell proliferation, however, 
7-day infusion of Notch antagonist post-injury greatly reduced injury-induced cell proliferation. 
We also found that ambiguous dose related responses wherein Notch agonist dose with higher 
and lower doses induce opposite effect on cell proliferation indicating more complicated 
mechanism involved.    
Studies have confirmed that cell proliferation persists throughout life in neurogenic 
niches such as SVZ and DG of mammalian and human brain (Boldrini et al., 2018, Gage 2000, 
Sun et al., 2016), and induction of proliferation and neurogenesis were observed in these 
neurogenic niche post TBI (Sun et al., 2005). Studies show the cell proliferation and 
differentiation in adult neurogenic niche is maintained by neural stem cell (NSC) in 
development and adulthood (Gage, 2000, Kreigstein, and Alvarez-Buylla, 2009). From the 
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embryonic development, it has been long known that, a highly conserved Notch signaling 
pathway functions as a core signaling system for maintenance and cell fate decision of NSCs 
(Artavanis-Tsakonas et al., 1999). Emerging evidences also support the involvement of Notch 
signaling pathway in regulating adult NSCs, the Notch pathway proteins are expressed in 
germinal zone of both embryonic and adult brains (Stump, 2002), and recent transgenic mice 
study has confirmed the involvement of Notch signaling in regulating maintenance of postnatal 
NSCs (Imayoshi et al., 2010). Moreover, Notch signaling pathway is also responsible for 
regulating neurogenesis in neurogenic niches during development and adulthood (Zhang et al., 
2015).  
The highly conserved cell to cell mediated canonical Notch signaling pathway is known 
to be responsible for regulating NSCs in neurogenic niche due to its downstream effectors such 
as Hes family, which is also known to regulate NSCs to take on either neuronal fate or maintain 
proliferative state (Kageyama et al., 2007). Generally, Notch ligand-receptor binding activates 
Notch signaling pathway and maintains NSCs into proliferative state, by upregulating Hes1 that 
is known to repress its own activity, it is known to induce neuronal cell differentiation by 
default. While unbound Notch receptors are thought to be constantly internalized and recycled, 
resulting the unrepressed Hes1 activity to induces cell differentiation (Kageyama et al., 2007, 
Zhang et al, 2014). Emerging evidences support the role of Notch signaling pathway in 
regulating NSC in neurogenic niches in development and adulthood, however the involvement 
of Notch signaling pathway in injury induced NSC proliferation in the neurogenic niche is not 
clear. 
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In the current study, we examined the effect of Notch pathway activation or inhibition 
on hippocampal neurogenesis and particularly assessed the optimal dose of the Notch agonist 
and antagonist on cell proliferation. We selected the doses based on published studies and 
used the cell proliferation marker Ki67 as the read out following 7-days infusion of the agonist 
or the antagonist.  We found that cell proliferation in the DG of hippocampus at day 7 post-
injury, was augmented by 7-day infusion of Notch agonists at the dose reported by other 
(Notch 1 -2ug/ml) and a further lower dose (Notch1-0.5μg/ml). This is consistent with ligand-
activated Notch signaling downstream effects. However, a higher dose of Notch agonist (Notch 
1-4μg/ml) infusion caused detrimental effect on injury induced cell proliferation in neurogenic 
niche, this suggests that the Notch1 signaling in regulating post-injury neurogenesis is more 
complicated than previously reported with over activation-inducing inhibition.  As only a few 
published studies which explored Notch activation on neurogenesis using the same Notch1 
antibody in other injury models all used Notch1 antibody at 2ug/ml (Sun et al., 2013, ), and no 
literatures have reported the inhibitory effect of high dose Notch activation, our finding needs 
to be further confirmed.  For Notch inhibitor, the dose of 50ug/ml was used by others (Sun et 
al., 2013, Wang et al., 2009), however, our Ki67 data found that 7-day infusion of Notch 
antagonist at lower dose of 25ug/ml significantly reduced injury-induced cell proliferation, 
whereas higher dose at 50ug/ml or 100ug/ml of Notch antagonist showed no effect on injury 
induced cell proliferation on 7th day, further suggesting a narrow window for pharmacological 
manipulation of Notch pathway activation.  It is noticed that the Ki67 data only represented the 
snapshot of cell proliferation at the time of perfusion, meaning 7 days after injury. Our previous 
study using pausing BrdU-labeling has shown that LFPI-induced cell proliferation in rats lasts at 
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least for 7 days (Sun et al., 2005), our Ki67 data of TBI only group is in agreement with this 
observation. However, what is intrigue is that all other injury groups with intraventricular 
infusion except Notch agonist at 2ug/ml had lower number of Ki67+ cell counts compared to 
the injury only group. This data suggests that extra surgical manipulation such as implantation 
of cannula and infusion of materials into the lateral ventricle affects cell proliferative response 
in the DG. As our study only observed NSC proliferation in the DG, the other neurogenic region- 
the SVZ, which is directly in contact with the lateral ventricle, was not assessed, this speculation 
is not conclusive.     
In pharmacological aspects, presence of ligand in high concentration generally means 
the better chance for ligands to bind to a receptor and able to induce its downstream effect. 
Although this is not always the case, the opposite effect that was produced between two Notch 
agonist doses (Notch1-2μg/ml) and (Notch1-4μg/ml) seems inexplicable. However, it is known 
that other Notch receptors are also expressed in adult hippocampus, Notch1 and Notch3 are 
expressed in dentate gyrus, and Notch2 is expressed in granular cell layer (Irvin et al., 2001). It 
is also reported that these receptors share Notch ligands such as Delta1, Jagged1, and Jagged2 
which known agonist for Notch1 and Notch3 receptors (Shimizu, 2000). Luciferase reporter 
studies also revealed that the transcriptional activities are markedly different from each other 
and dependent on different promoters, also Notch1 and Notch3 activities were reduced by 
expression of Notch2, suggesting each Notch receptor has a diverse role in the downstream 
gene expression, and Hes1 and Hes5 gene expression maybe complexly dependent on various 
factors such as combination of Notch receptors (Shimizu, 2002). Perhaps 7-day infusion of 
higher concentration exogenous Notch1 agonist (Notch1-4μg/ml), Notch1 activation antibody 
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that exclusively detects & binds to Notch1 receptor only, may have led to overly occupied 
Notch1 receptors, forcing other endogenous Notch ligands to bind to other Notch2, or Notch3 
receptors, involuntarily activating them. Adding to the fact that Notch activity is already 
elevated due to TBI (Tatsumi, 2010) and upregulation of Notch ligands from other intersecting 
signaling pathways possibly upon onset of TBI (D’Souza et al., 2010, Hurlbut, 2007, Table 1.1) 
these factors collectively could have created a mayhem of Notch activities between Notch1, 
Notch2, Notch3 downstream expressions leading to the detrimental effect on injury induced 
cell proliferation, since co-expression of Notch2 reduced activity of Notch1 and Notch3 
(Shimizu, 2002).   
For Notch1 antagonist dose response study, it is not clear why higher dose has no effect 
on cell proliferation inhibition. The exogenous Notch antagonist, Jagged1 fusion protein binds 
to all Notch receptors, possibly to Notch1 and Notch3 with higher affinity since Jagged1 is one 
of known ligands for those receptors (Shimizu, 2000). Affinity between Jagged1 fc, Deltalike1, 
Jagged1 and Jagged2 are unknown, but exogenous inhibitors such as Jagged1 fusion protein are 
often engineered to possess higher affinity to receptors than other endogenous counterparts 
inhibiting Notch1 and possibly Notch3. The interaction of downstream signaling pathways 
between reduced activity of Notch1 and Notch3 and possible increased activity of Notch2 
receptors are unknown.  
To quantify accumulated cell proliferation and surviving cells in the DG of hippocampus, 
we used BrdU as the marker. Due to the labor intensity and time limitation, we only quantified 
the number of BrdU+ cells at one dose for both Notch agonist and antagonist. We found that 
BrdU cell counts were increased compared to sham in all injury group except the Notch 
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antagonist treated group. This confirmed that there is an injury-induced cell proliferation in the 
DG during the 7-day period post-injury. However, infusion of Notch agonist does not further 
augment this injury effect. As TBI enhances Notch expression in the neurogenic regions, the 
Notch effect on NSC proliferation is probably already saturated, thus exogenous Notch activator 
would not have further effect.   The BrdU data has showed that 7-day infusion of Notch 
antagonist at 50μg/ml greatly reduced injury induced cell proliferation suggesting that Notch 
signaling is indeed involved in NSC proliferation following injury.  
 Notch signaling activation or inhibition on generation of new neurons in the DG of 
hippocampus was assessed by quantifying the number of DCX+ cells. We found that in 
correlation to cell proliferation, that animals groups with lower number of Ki67 cell counts had 
higher number of DCX+ cells (TBI-veh, TBI-Notch1-4ug/ml), whereas animals groups with higher 
Ki67+cell counts (TBI-only, TBI-Notch1-2ug/ml) had lower number of DCX+ cells in both the 
granular zone and hilus regions. This suggests that when NSC proliferation is increased, less 
cells are differentiated (Notch activation), whereas when NCS proliferation is inhibited, more 
cells are becoming differentiated (Notch inhibition). This confirms the important role of Notch 
in maintaining the proliferation pool of NSCs, as studies  have reported enhanced neurogenesis 
(NSCs going on differentiation into neurons) in the neurogenic niche in the absence of Notch 
activity (Borghese et al., 2010, Chen et., al 2014, Falk et al., 2012, Wang et al., 2004).   
Further work to complete the quantification of the number of BrdU+ cells at other two 
doses of Notch agonist and antagonist will provide better information about the dose response 
effect of Notch activation/inhibition on neurogenesis. Further studies involving various Notch 
agonists targeted for Notch1, Notch2, and Notch3, and antagonists for DSL ligands including 
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Delta-like1, Jagged1, and Jagged2 would allow closer examination of Notch signaling pathways 
involved with injury induced cell proliferation in neurogenic niche. Moreover, proliferated cells 
could be double labeled with cell proliferation marker and neuronal /glial markers to further 
investigate injury induced neuronal or glial cell fate induced by downstream effectors of each 
signaling pathways by Notch1, Notch2, or Notch3 receptors. Further, in combination of 
receptors to discover possible downstream interactions among Notch receptors that are 
expressed in the adult DG of hippocampus. This clarification could potentially allow precise 
pharmaceutical manipulation of brain’s innate ability to repair and regenerate post-TBI.     
 
Summary 
Notch signaling pathway maybe involved in injury induced NSC cell proliferation in the 
neurogenic niche. Our data showed varying results confirming the involvement of Notch 
singling pathway in injury induced NSC cell proliferative response.  However, some intriguing 
data indicated a more complicated interaction of other Notch receptors in neurogenic niches, 
which shares same ligands and possibly can produce different downstream effects depending 
on their own signaling mechanisms and effectors involved. Further studies and understanding 
of each Notch receptors could potentially allow precise pharmaceutical manipulation of brain’s 
innate ability to repair and regenerate post-TBI.     
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